 Farahnak Assadi
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 10 | 2019 | 212 | 3.580 |
Why?
| | Kidney Failure, Chronic | 4 | 2019 | 152 | 2.140 |
Why?
| | Renal Insufficiency, Chronic | 4 | 2019 | 80 | 1.840 |
Why?
| | Child | 19 | 2019 | 1335 | 1.810 |
Why?
| | Acute Kidney Injury | 3 | 2019 | 41 | 1.770 |
Why?
| | Allopurinol | 2 | 2018 | 7 | 1.510 |
Why?
| | Albuminuria | 4 | 2007 | 23 | 1.450 |
Why?
| | Hypertrophy, Left Ventricular | 3 | 2007 | 28 | 1.230 |
Why?
| | Adolescent | 16 | 2019 | 2303 | 1.220 |
Why?
| | Antihypertensive Agents | 4 | 2013 | 62 | 1.200 |
Why?
| | Kidney Transplantation | 3 | 2013 | 122 | 1.160 |
Why?
| | Hyperuricemia | 2 | 2018 | 5 | 1.010 |
Why?
| | Child, Preschool | 8 | 2019 | 725 | 0.970 |
Why?
| | Humans | 35 | 2019 | 25751 | 0.970 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 63 | 0.940 |
Why?
| | Shock | 1 | 2019 | 6 | 0.930 |
Why?
| | Kidney | 2 | 2018 | 179 | 0.910 |
Why?
| | Sodium | 3 | 2015 | 67 | 0.810 |
Why?
| | Prospective Studies | 8 | 2019 | 1522 | 0.800 |
Why?
| | C-Reactive Protein | 2 | 2007 | 129 | 0.780 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 7 | 0.750 |
Why?
| | Hemofiltration | 1 | 2016 | 8 | 0.750 |
Why?
| | Hypokalemia | 2 | 2008 | 7 | 0.740 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 18 | 0.730 |
Why?
| | Diabetes Insipidus, Nephrogenic | 1 | 2015 | 2 | 0.700 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2015 | 4 | 0.700 |
Why?
| | Algorithms | 3 | 2012 | 379 | 0.680 |
Why?
| | Risk Factors | 7 | 2019 | 2208 | 0.660 |
Why?
| | Enalapril | 1 | 2013 | 3 | 0.650 |
Why?
| | Evidence-Based Medicine | 3 | 2010 | 207 | 0.650 |
Why?
| | Antimetabolites | 1 | 2013 | 13 | 0.640 |
Why?
| | Male | 18 | 2019 | 14947 | 0.630 |
Why?
| | Critical Care | 1 | 2016 | 188 | 0.610 |
Why?
| | Pediatrics | 1 | 2013 | 50 | 0.600 |
Why?
| | Physician's Role | 1 | 2013 | 19 | 0.600 |
Why?
| | Gout | 1 | 2012 | 7 | 0.590 |
Why?
| | Creatinine | 4 | 2019 | 55 | 0.590 |
Why?
| | Hydronephrosis | 1 | 2012 | 7 | 0.590 |
Why?
| | Hyponatremia | 1 | 2012 | 8 | 0.590 |
Why?
| | Fluid Therapy | 3 | 2012 | 27 | 0.580 |
Why?
| | Kidney Diseases | 2 | 2006 | 133 | 0.570 |
Why?
| | Female | 16 | 2019 | 15304 | 0.560 |
Why?
| | HELLP Syndrome | 1 | 2010 | 2 | 0.530 |
Why?
| | Maternal-Fetal Exchange | 1 | 2010 | 12 | 0.530 |
Why?
| | Placenta | 1 | 2010 | 14 | 0.520 |
Why?
| | Infant | 4 | 2019 | 573 | 0.520 |
Why?
| | Hypophosphatemia | 1 | 2010 | 1 | 0.510 |
Why?
| | Disease Progression | 4 | 2019 | 734 | 0.510 |
Why?
| | Nephrotic Syndrome | 1 | 2010 | 31 | 0.510 |
Why?
| | Magnesium Deficiency | 1 | 2010 | 1 | 0.500 |
Why?
| | Gitelman Syndrome | 1 | 2010 | 1 | 0.500 |
Why?
| | Inflammation Mediators | 1 | 2010 | 80 | 0.490 |
Why?
| | Magnesium | 1 | 2010 | 49 | 0.480 |
Why?
| | Hypercalcemia | 1 | 2009 | 8 | 0.470 |
Why?
| | Purpura, Schoenlein-Henoch | 1 | 2009 | 3 | 0.460 |
Why?
| | Glomerulonephritis | 1 | 2009 | 25 | 0.450 |
Why?
| | Anemia, Hemolytic, Congenital | 1 | 2008 | 1 | 0.450 |
Why?
| | Acid-Base Imbalance | 1 | 2008 | 2 | 0.450 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2008 | 9 | 0.450 |
Why?
| | Catecholamines | 1 | 2008 | 16 | 0.450 |
Why?
| | Transfusion Reaction | 1 | 2008 | 10 | 0.440 |
Why?
| | Cytokines | 1 | 2010 | 334 | 0.440 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 28 | 0.400 |
Why?
| | Cerebellum | 1 | 2007 | 53 | 0.390 |
Why?
| | Blood Pressure | 4 | 2013 | 208 | 0.380 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2006 | 1 | 0.380 |
Why?
| | Acidosis, Renal Tubular | 1 | 2006 | 2 | 0.380 |
Why?
| | Premedication | 1 | 2006 | 7 | 0.380 |
Why?
| | Rett Syndrome | 1 | 2006 | 4 | 0.380 |
Why?
| | Acetazolamide | 1 | 2006 | 3 | 0.380 |
Why?
| | Hyperkalemia | 1 | 2006 | 5 | 0.380 |
Why?
| | Uric Acid | 2 | 2018 | 11 | 0.380 |
Why?
| | Infant, Newborn | 4 | 2012 | 630 | 0.380 |
Why?
| | Nail Diseases | 1 | 2005 | 1 | 0.360 |
Why?
| | Strontium | 1 | 2005 | 2 | 0.360 |
Why?
| | Transcription Factors | 1 | 2007 | 165 | 0.360 |
Why?
| | Hematuria | 1 | 2005 | 15 | 0.360 |
Why?
| | Autonomic Dysreflexia | 1 | 2004 | 1 | 0.350 |
Why?
| | Contrast Media | 1 | 2006 | 141 | 0.340 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2004 | 5 | 0.340 |
Why?
| | Down Syndrome | 1 | 2004 | 10 | 0.340 |
Why?
| | Kidney Glomerulus | 1 | 2005 | 82 | 0.340 |
Why?
| | Immunoglobulin G | 1 | 2004 | 134 | 0.320 |
Why?
| | Diarrhea | 1 | 2003 | 59 | 0.310 |
Why?
| | Pheochromocytoma | 1 | 2003 | 8 | 0.310 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2003 | 13 | 0.300 |
Why?
| | Germ-Line Mutation | 1 | 2003 | 6 | 0.300 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2003 | 39 | 0.300 |
Why?
| | Tumor Suppressor Proteins | 1 | 2003 | 34 | 0.300 |
Why?
| | Cystinosis | 1 | 2002 | 1 | 0.290 |
Why?
| | Alkalosis | 1 | 2002 | 2 | 0.290 |
Why?
| | Failure to Thrive | 1 | 2002 | 3 | 0.290 |
Why?
| | Constipation | 1 | 2002 | 34 | 0.290 |
Why?
| | Adult | 7 | 2012 | 8405 | 0.280 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2002 | 31 | 0.280 |
Why?
| | Treatment Outcome | 3 | 2018 | 3223 | 0.270 |
Why?
| | Interleukin-18 | 1 | 2019 | 10 | 0.230 |
Why?
| | Area Under Curve | 1 | 2019 | 73 | 0.230 |
Why?
| | Anti-Inflammatory Agents | 2 | 2010 | 97 | 0.230 |
Why?
| | ROC Curve | 1 | 2019 | 118 | 0.220 |
Why?
| | Pediatric Obesity | 1 | 2019 | 34 | 0.220 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 553 | 0.210 |
Why?
| | Age Factors | 2 | 2013 | 794 | 0.210 |
Why?
| | Prevalence | 1 | 2019 | 477 | 0.200 |
Why?
| | Radiography | 2 | 2012 | 687 | 0.200 |
Why?
| | Risk Assessment | 2 | 2012 | 675 | 0.190 |
Why?
| | Diuretics | 2 | 2009 | 13 | 0.190 |
Why?
| | Pharmacokinetics | 1 | 2016 | 6 | 0.190 |
Why?
| | Renal Replacement Therapy | 1 | 2016 | 19 | 0.180 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 765 | 0.180 |
Why?
| | Risk | 1 | 2016 | 205 | 0.180 |
Why?
| | Aquaporin 2 | 1 | 2015 | 1 | 0.180 |
Why?
| | Urine | 1 | 2015 | 7 | 0.170 |
Why?
| | Cyclic GMP | 1 | 2015 | 16 | 0.170 |
Why?
| | Osmolar Concentration | 1 | 2015 | 36 | 0.170 |
Why?
| | Urinalysis | 1 | 2015 | 10 | 0.170 |
Why?
| | Critical Illness | 1 | 2016 | 87 | 0.170 |
Why?
| | Drug Synergism | 1 | 2013 | 65 | 0.160 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 250 | 0.150 |
Why?
| | Insurance, Health | 1 | 2013 | 22 | 0.150 |
Why?
| | Saline Solution, Hypertonic | 1 | 2012 | 1 | 0.150 |
Why?
| | Urethral Obstruction | 1 | 2012 | 1 | 0.150 |
Why?
| | Vesico-Ureteral Reflux | 1 | 2012 | 7 | 0.150 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 62 | 0.150 |
Why?
| | Syndrome | 2 | 2003 | 102 | 0.150 |
Why?
| | Ureteral Obstruction | 1 | 2012 | 15 | 0.140 |
Why?
| | Urethra | 1 | 2012 | 16 | 0.140 |
Why?
| | Ultrasonography, Prenatal | 1 | 2012 | 25 | 0.140 |
Why?
| | Urinary Bladder | 1 | 2012 | 20 | 0.140 |
Why?
| | Early Diagnosis | 1 | 2012 | 65 | 0.140 |
Why?
| | Down-Regulation | 1 | 2012 | 135 | 0.140 |
Why?
| | Fetal Blood | 1 | 2010 | 19 | 0.130 |
Why?
| | Patient Education as Topic | 1 | 2013 | 181 | 0.130 |
Why?
| | Patient Care Team | 1 | 2012 | 112 | 0.130 |
Why?
| | Calcitriol | 1 | 2010 | 6 | 0.130 |
Why?
| | Phosphates | 1 | 2010 | 14 | 0.130 |
Why?
| | Interleukin-1beta | 1 | 2010 | 54 | 0.130 |
Why?
| | Patient Selection | 1 | 2012 | 227 | 0.130 |
Why?
| | Vitamins | 1 | 2010 | 15 | 0.130 |
Why?
| | Life Style | 1 | 2012 | 173 | 0.130 |
Why?
| | Hydrocortisone | 1 | 2010 | 45 | 0.130 |
Why?
| | Interleukin-6 | 1 | 2010 | 114 | 0.120 |
Why?
| | Problem Solving | 1 | 2010 | 45 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 250 | 0.120 |
Why?
| | Pregnancy | 1 | 2010 | 364 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 229 | 0.120 |
Why?
| | Furosemide | 1 | 2009 | 2 | 0.120 |
Why?
| | Hyperparathyroidism | 1 | 2009 | 7 | 0.120 |
Why?
| | Education, Medical, Continuing | 1 | 2010 | 42 | 0.120 |
Why?
| | Renin | 1 | 2008 | 4 | 0.110 |
Why?
| | Potassium | 1 | 2008 | 66 | 0.110 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 5 | 0.100 |
Why?
| | Kidney Diseases, Cystic | 1 | 2007 | 2 | 0.100 |
Why?
| | Electroretinography | 1 | 2007 | 3 | 0.100 |
Why?
| | Young Adult | 1 | 2013 | 1798 | 0.100 |
Why?
| | Blindness | 1 | 2007 | 12 | 0.100 |
Why?
| | Neoplasms | 1 | 2009 | 222 | 0.100 |
Why?
| | Regression Analysis | 1 | 2007 | 304 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 203 | 0.090 |
Why?
| | Water Supply | 1 | 2005 | 4 | 0.090 |
Why?
| | Glomerulonephritis, IGA | 1 | 2005 | 5 | 0.090 |
Why?
| | Labetalol | 1 | 2004 | 4 | 0.090 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2004 | 4 | 0.090 |
Why?
| | Glomerular Mesangium | 1 | 2004 | 3 | 0.090 |
Why?
| | Drainage | 1 | 2004 | 53 | 0.080 |
Why?
| | Spinal Neoplasms | 1 | 2004 | 33 | 0.080 |
Why?
| | Dehydration | 1 | 2003 | 4 | 0.080 |
Why?
| | Cohort Studies | 1 | 2009 | 1557 | 0.080 |
Why?
| | Microcephaly | 1 | 2003 | 1 | 0.080 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2003 | 1 | 0.080 |
Why?
| | Hearing Loss, Bilateral | 1 | 2003 | 4 | 0.080 |
Why?
| | Cryptorchidism | 1 | 2003 | 4 | 0.080 |
Why?
| | Genes, Tumor Suppressor | 1 | 2003 | 13 | 0.080 |
Why?
| | Serine | 1 | 2003 | 15 | 0.080 |
Why?
| | Glycine | 1 | 2003 | 10 | 0.080 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2003 | 8 | 0.080 |
Why?
| | Ligases | 1 | 2003 | 13 | 0.080 |
Why?
| | von Hippel-Lindau Disease | 1 | 2003 | 5 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2003 | 27 | 0.080 |
Why?
| | Amino Acid Substitution | 1 | 2003 | 40 | 0.080 |
Why?
| | Developmental Disabilities | 1 | 2003 | 21 | 0.070 |
Why?
| | Spironolactone | 1 | 2002 | 2 | 0.070 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2002 | 3 | 0.070 |
Why?
| | Amiloride | 1 | 2002 | 8 | 0.070 |
Why?
| | Electrolytes | 1 | 2002 | 13 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2002 | 26 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2002 | 55 | 0.070 |
Why?
| | Random Allocation | 1 | 2002 | 141 | 0.070 |
Why?
| | Specimen Handling | 1 | 2002 | 46 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 1058 | 0.070 |
Why?
| | Ultrasonography | 1 | 2002 | 179 | 0.070 |
Why?
| | Retrospective Studies | 1 | 2009 | 2591 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 442 | 0.060 |
Why?
| | Chronic Disease | 1 | 2002 | 465 | 0.060 |
Why?
|
|
Assadi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|